Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIQURE BIOPHARMA B.V. currently manages 4 pending office actions in the Biotechnology & Pharmaceuticals area. This count is identical to the number of 4 distinct examiners, while the portfolio spans 3 distinct art units. CORNELIUS, CLAIRE ADRIENNE is the busiest examiner with 1 pending office action.
The presence of 3 distinct art units indicates that the company's biopharmaceutical innovations are being evaluated across several specialized technical classifications. With 1 pending office action assigned to the busiest examiner, the remaining matters are distributed among other individuals and units at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNELIUS, CLAIRE ADRIENNE | 1 | 66.7% | +0.0% |
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
| POPA, ILEANA | 1 | 21.4% | +15.1% |
| LEVIN, JOEL D | 1 | 58.1% | +35.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564621 | Insect cell production of parvoviral vectors with modified capsid proteins | CORNELIUS, CLAIRE ADRIENNE | — |
| 18375392 | METHODS FOR PRODUCING SINGLE INSECT CELL CLONES | POPA, ILEANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17948862 | NOVEL CELL LINE | LEVIN, JOEL D | 42d |
| 18556163 | METHODS AND MEANS FOR THE PREVENTION AND/OR TREATMENT OF HEMOPHILIC ARTHROPATHY IN HEMOPHILIA | MARVICH, MARIA | — |
| 18375392 | METHODS FOR PRODUCING SINGLE INSECT CELL CLONES | POPA, ILEANA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| 1672 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18564621 | Insect cell production of parvoviral vectors with modified capsid proteins | CORNELIUS, CLAIRE ADRIENNE | 1672 | §103§112 | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18556163 | METHODS AND MEANS FOR THE PREVENTION AND/OR TREATMENT OF HEMOPHILIC ARTHROPATHY IN HEMOPHILIA | MARVICH, MARIA | 1634 | §103§112DP | Final Rejection | — | Pending | Oct 19, 2023 |
| 18375392 | METHODS FOR PRODUCING SINGLE INSECT CELL CLONES | POPA, ILEANA | 1633 | §103§112 | Final Rejection | — | Pending | Sep 29, 2023 |
| 17948862 | NOVEL CELL LINE | LEVIN, JOEL D | 1633 | Other | Non-Final OA | 42d | Pending | Sep 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial